Core A: Administrative

NIH Pandemic-Era Grants

Pandemic Era Grants

2023

↗ Live URL (may be dead)

Document text

Principal Investigator: DREW  WEISSMAN
Organization: UNIVERSITY OF PENNSYLVANIA
Fiscal Year: 2023
Award: $87,740
Funding agency: National Institute of Allergy and Infectious Diseases

SUMMARY – CORE A (Administration Core)
The "mRNA Vaccines for C. difficile Suppression” program (mVACS) consists of a highly interactive team of
investigators who are seeking to develop an mRNA vaccine platform to provide protection against
Clostridioides difficile-associated infection and disease. Project 1 is the engine for generating and testing
modified mRNA vaccines (Project 1 – Vaccine Development). This effort is accelerated and guided by
projects exploring strain diversity and microbial ecology (Project 2 – Antigen Discovery) and the mucosal
adaptive immune response to natural infection (Project 3 – Immunology). Supporting these three projects are
two scientific cores that will provide expertise, technical skills, and analysis of large deep-sequencing datasets
(Core B - Genomics Core), and collect samples for a patient cohort (Core C - Clinical Core). Core A
(Administrative Core) is the logistical and organizational component of the program that will handle regular
inter-project communication and ensure seamless exchange of data and information. Core A (Administrative
Core) is co-led by the mVACS program directors Dr. Bushman and Dr. Weissman. Their primary objectives will
be to monitor the scientific progress of the program, oversee distribution of resources, stimulate project
interactions and data integration, ensure compliance with NIH guidelines, and promote the scientific career
development of the mVACS team.

Terms: <2019-nCoV vaccine><Academia><Acceleration><Antigens><Bionomics><Budgets><C diff><C difficile><C. diff><C. difficile><COVID-19 vaccine><COVID19 vaccine><Children's Hospital><Clinical><Clostridioides difficile><Clostridium difficile><Communication><Complement><Complement Proteins><Data><Data Set><Disease><Disorder><Ecology><Electronics><Elements><Ensure><Faculty><Feedback><Florida><Fostering><Funding><Generalized Growth><Genomic approach><Genomics><Goals><Growth><Guidelines><Immune response><Immunization><Immunological response><Immunology><Infection><Institution><International><Investigators><Lead><Leadership><Letters><Measures><Mentors><Messenger RNA><Monitor><Mucosa><Mucosal Tissue><Mucous Membrane><NIH><National Institutes of Health><North Carolina><Patients><Pb element><Pediatric Hospitals><Pennsylvania><Persons><Philadelphia><RNA vaccine><RNA-based vaccine><Research Activity><Research Personnel><Research Resources><Researchers><Resource Sharing><Resources><SARS-CoV-2 vaccine><SARS-CoV2 vaccine><SARS-coronavirus-2 vaccine><Sampling><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Structure><Supervision><Technical Expertise><Testing><Tissue Growth><Toxin><Training><United States National Institutes of Health><Universities><Vaccines><Work><adaptive immune response><career development><cohort><conference><convention><corona virus disease 2019 vaccine><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><data exchange><data integration><data transfer><data transmission><deep sequencing><design><designing><develop a vaccine><develop vaccines><development of a vaccine><electronic><electronic device><experience><experiment><experimental research><experimental study><experiments><genomic effort><genomic strategy><heavy metal Pb><heavy metal lead><host response><immune system response><immunogen><immunoresponse><industrial partnership><industry partner><industry partnership><mRNA><mRNA vaccine><mRNA-based vaccine><meeting><meetings><member><microbial><mouse model><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><novel><ontogeny><prevent><preventing><programs><recruit><summit><symposia><symposium><technical skills><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine development><vaccine for novel coronavirus><vaccine platform><vaccinology><virtual>